Skip to Content
UW Health SMPH
American Family Children's Hospital
DONATE Donate
SHARE TEXT
Sam J. Lubner, MD close
JBoSyXtT9VU
Sam J. Lubner, MD
 

Sam J. Lubner, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Lubner graduated from Princeton University, Princeton, NJ, with a BA in History in 1999, and the University of Wisconsin School of Medicine, Madison, WI with a MD, in 2003. His postgraduate internship and residency training in Internal Medicine was performed at Washington University School of Medicine, Barnes-Jewish Hospital, Saint Louis, MO from 2003 to 2006, and a fellowship in Hematology/Oncology at University of Wisconsin Hospital and Clinics, Madison, WI.

Specialties

Medical Oncology

UW Health Clinics

UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map
UW Hospital and Clinics
(608) 263-7502 | (800) 323-8942 | Map
UW Carbone Cancer Center
(608) 265-1700 | (800) 323-8942 | Map

Other Locations

Beaver Dam Community Hospital (Beaver Dam)
(920) 887-4105  | (888) 703-2778 |  Map

Hospital Affiliation(s)

University of Wisconsin Hospital and Clinics (primary)

Languages Spoken

English
Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.

UW School of Medicine and Public Health

Department of Medicine

Professional Certifications and Education

Board Certification Internal Medicine
Fellowship University of Wisconsin Hospital and Clinics, Madison, WI
Residency Barnes-Jewish Hospital, St. Louis, MO
Internship Barnes-Jewish Hospital, St. Louis, MO
Medical School University of Wisconsin School of Medicine and Public Health, Madison, WI, 2003

Awards/Honors

Madison Magazine Top Docs 2012


PubMed Articles
LoConte NK Holen KD Schelman WR Mulkerin DL Deming DA Hernan HR Traynor AM Goggins T Groteluschen D Oettel K Robinson E Lubner SJ . A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study. Invest New Drugs. 2013 Aug;31(4):943-8
[PubMed ID: 23263993]
Mohammed TA Holen KD Jaskula-Sztul R Mulkerin D Lubner SJ Schelman WR Eickhoff J Chen H Loconte NK . A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Oncologist. 2011;16(6):835-43
[PubMed ID: 21632454]
Lubner SJ Kunnimalaiyaan M Holen KD Ning L Ndiaye M Loconte NK Mulkerin DL Schelman WR Chen H . A preclinical and clinical study of lithium in low-grade neuroendocrine tumors. Oncologist. 2011;16(4):452-7
[PubMed ID: 21393344]
Lubner SJ Mahoney MR Kolesar JL Loconte NK Kim GP Pitot HC Philip PA Picus J Yong WP Horvath L Van Hazel G Erlichman CE Holen KD . Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study. J Clin Oncol. 2010 Jul 20;28(21):3491-7
[PubMed ID: 20530271]
Lubner SJ Loconte NK Holen KD Schelman W Thomas JP Jumonville A Eickhoff JC Seo S Mulkerin DL . A phase II study of oxaliplatin, 5-fluorouracil, leucovorin, and high-dose capecitabine in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2010 Jul;9(3):157-61
[PubMed ID: 20643620]